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Abstract 
Ovarian hyperstimulation syndrome (OHSS) is a 
relatively common complication in infertile 
patients treated with exogenous gonadotropins. 
Ovarian hyperstimulation in spontaneous 
pregnancies is a rare but possible. The 
pathogenesis of spontaneous OHSS is not well 
known. Risk factors for OHSS are young age, 
polycystic ovaries, low body mass index, high 
gonadotropin dose, increased estradiol and 
human chorionic gonadotropin levels, multiple 
pregnancy, OHSS history, molar pregnancy and 
hypothyroidism. In this report we present a case 
of severe spontaneous OHSS with a brief 
summary of the literature. She was hospitalized 
and treated in the clinic with the diagnosis of 
severe OHSS accompanying spontaneous 
pregnancy.  
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Introduction 
Ovarian hyperstimulation syndrome is a 
relatively common iatrogenic 
complication of ovulation induction and 
controlled ovarian hyperstimulation 
induced with exogenous gonadotropins.1 
The incidence of OHSS is about 1-10% 
and severe OHSS is seen in less than 
2% of cases.2 Massive ovarian 
enlargement, multiple cysts, ascites, 
oliguria, abdominal pain, 
hemoconcentration, thrombosis, pleural 
effusion, electrolyte imbalance, renal 
failure, acute respiratory distress 
syndrome, hypovolemia and death can 
accompany severe OHSS.3 OHSS 
following spontaneous ovulation is very 
rare. In this report, a case of severe 
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OHSS accompanying spontaneous 
singleton pregnancy is summarized. 
Case Report 
A 27 year-old gravida 3 para 2 woman 
presented to the clinic with a complaint 
of abdominal pain, abdominal 
distension, dyspnea, nausea and 
vomiting. She previously had two 
healthy deliveries at term. The medical 
history was uneventful and no drug use 
was reported before or during the 
pregnancy. 
Vital signs of the patient were normal. 
Abdominal distension and bilateral 
adnexal pain were noted during the 
physical examination Transabdominal 
ultrasonography revealed a 10-week, 
singleton pregnancy. Both of the ovaries 
were enlarged and multicystic (Left 
ovary: 118 x 113 mm, right ovary: 127 x 
117) and there were ascites in the 
abdomen. 
 
Picture 1. Left Ovary 
Blood tests revealed hemoconcentration 
(Hb: 16.7 g/dl, Htc: 47.40%, WBC: 
25260, PLT: 360000/mm3), 
hyponatremia (Na: 123 mmol/l), 
hypocalcaemia (7.77 mg/dl), 
hypoproteinemia (Albumin: 2.2 g/l).  
The patient was hospitalized with the 
diagnosis of severe spontaneous OHSS 
and treated with intravenous fluid 
replacement, albumin infusion, and low 
molecular weight heparin. A specialist 
performed respiratory physiotherapy. 
Daily weight and abdominal 
circumference measurements were 
performed. Blood tests were also 
repeated daily and treatment of the 
patient was managed accordingly.  
 
Picture 2. Right Ovary 
After the first week of hospitalization, an 
increase in body weight and abdominal 
circumference was seen. The patient 
had dyspnea, and there was bilateral 
pleural effusion in the chest x-ray and 
thoracic ultrasonography. Thoracentesis 
was performed. The fluid was transude 
in manner and both cytological and 
microbiological examinations were 
normal. There was an increase in the 
ovarian size (left ovary: 176 x 139 mm, 
right ovary: 166 x 132 mm) (Picture 1, 
Picture 2). Cabergoline 0.5 mg/day and 
dexamethasone 0.5 mg/day treatment 
was started. 
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After four weeks of treatment abdominal 
distension and dyspnea were dissolved 
and laboratory tests were normalized. 
The patient was discharged at 14th 
weeks of gestation. She was seen at 
regular visits and delivered uneventfully 
at the 37th week of pregnancy. 
Discussion 
Ovarian hyperstimulation syndrome 
(OHSS) is an iatrogenic complication of 
exogenous gonadotropins or sometimes 
clomiphene citrate used for ovulation 
induction.4 The incidence is about 1-
10% and the severe form constitutes 
about 1-2% of the cases. Major risk 
factors are; young age, PCOS, lean 
body weight, high dose gonadotropins 
use, elevated estradiol and human 
chorionic gonadotropin (hCG) levels, 
previous OHSS, molar pregnancy, 
multiple pregnancy and hypothyroidism.6 
This case had none of these risk factors. 
Molecular FSH receptor gene defects 
have been shown in recurrent OHSS 
cases in some families.7 There was not 
such a finding in our case.  
Spontaneous OHSS is a rare entity. De 
Leener et al. classified spontaneous 
OHSS into three types: Type I: caused 
by FSH receptor mutations; Type II: 
caused by elevated hCG; Type III: 
hypothyroidism related.8 In both type I 
and type II development of OHSS is 
hCG mediated. Mutations in FSH 
receptors may cause increased 
sensitivity to hCG. Although there is a 
case of spontaneous OHSS in a non-
pregnant adolescent with recurrent 
OHSS almost all cases in the literature 
were pregnant.9 In this case, since our 
center does not have the necessary set 
up, we could not test for FSH receptor 
mutations.  
Vascular endothelial growth factor 
(VEGF) is blamed as the cause of fluid 
loss to the third space, hypovolemia, 
hemoconcentration and electrolyte 
imbalance. VEGF changes the structure 
of endothelial gap junctions and 
increases vascular permeability.10 In this 
case we saw pleural effusion, ascites, 
hemoconcentration, hypovolemia, and 
vulvar edema assumed to be related to 
VEGF. Expression of VEGF mRNA has 
been shown to be induced by hCG in a 
dose- and time-dependent fashion.11 It 
was shown that VEGF mRNA 
expression is increased after luteinizing 
hormone (LH) surge.12,13 Molecular 
similarity between LH and hCG is 
important for both progression of the 
disease and prevention strategies. 
Dopamine receptor-2 agonist activation 
decreases ovarian VEGF production 
and prevents vascular permeability in 
OHSS rat models.14 Polymorphism of 
VEGF receptor gene itself may also be 
associated with the occurrence of 
OHSS.15  
OHSS can be classified as mild, 
moderate, and severe.16 Mild and 
moderate cases have a good prognosis, 
usually recovering spontaneously or 
with conservative management. Severe 
cases need inpatient care. This was a 
case of severe OHSS. In the 
management of these patients, close 
follow up of vitals, body weight, 
abdominal circumference, and fluid 
balance is crucial. Blood tests must be 
checked frequently.17 Hyponatremia is a 
common finding in these patients. 
Crystalloids are the first choice for fluid 
replacement. Daily fluid needs change 
from 1.5 to 3 L. Volume expanders such 
as dextran, albumin, hydroxyethyl starch 
(HES), and fresh plasma can also be 
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used.1 Prophylactic use of heparin is 
necessary for thromboprophylaxis in 
patients at risk of thromboembolism. 
Cabergoline is a dopamine receptor 
agonist that decreases vascular 
permeability by inhibiting VEGF 
receptors.18 Steroids are effective since 
there is an inflammatory response in 
OHSS.19 In our case cabergoline and 
steroids were used since there was a 
progression in the disease. After 4 
weeks of treatment, clinical and 
laboratory findings were normalized in 
our case and the patient was discharged 
from the hospital. She delivered 
uneventfully at 37th week of gestation. 
Cabergoline, when given at the time of 
diagnosis of OHSS, appears to work 
rapidly and effectively to diminish the 
clinical symptoms of the disease. 
Conclusion 
Severe OHSS is a life threatening 
complication of ovarian 
hyperstimulation. Spontaneous OHSS is 
a rare entity, which occurs in gestations 
without ovulation induction. Early 
diagnosis may prevent unwanted results 
of the disease.  
This study was presented at the Palandöken 
Gynecology and Obstetrics Winter Congress, 
05-08 March 2014 Erzurum/ TURKEY. 
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